{"id":1013176,"date":"2026-10-23T10:35:24","date_gmt":"2026-10-23T14:35:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/"},"modified":"2026-10-23T10:35:24","modified_gmt":"2026-10-23T14:35:24","slug":"kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/","title":{"rendered":"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Durable results extending beyond two years in the first patient treated<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027<\/em>\n      <\/p>\n<p>EMERYVILLE, Calif., Oct.  23, 2026  (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1 investigator-initiated trial (IIT) of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with progressive multiple sclerosis (PMS). The data will be shared today in an oral presentation at MS Toronto 2026, the joint ACTRIMS-ECTRIMS meeting.<\/p>\n<p>\u201cThere remains a substantial unmet need for therapies that can meaningfully alter the course of progressive multiple sclerosis,\u201d said Jeffrey Dunn, MD, Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology at Stanford University. \u201cIn this early-phase study, miv-cel demonstrated encouraging tolerability, with evidence of CAR T-cell penetration into the central nervous system and biologic findings consistent with an immune reset. Importantly, we also observed sustained improvements in measures of neurologic disability and patient-reported function among evaluable participants. While these preliminary findings require confirmation in larger controlled trials, they provide an important proof of concept that miv-cel may offer a potential novel approach to treating progressive multiple sclerosis.\u201d<\/p>\n<p>\n        <strong><br \/>\n          <u>Stanford Oral Presentation<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Safety and Preliminary Efficacy of CD-19 Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: A Phase 1 Study<br \/><strong>Presenter: <\/strong>Jeff Dunn, M.D., Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology, Stanford University<br \/><strong>Date &amp; Time:<\/strong> Friday, October 23, 2026, 11:05 \u2013 11:15 AM ET<\/p>\n<p>Stanford University is conducting an open-label, Phase 1, single-center study of miv-cel in patients with non-relapsing progressive multiple sclerosis, either secondary progressive MS (SPMS) or primary progressive MS (PPMS). Six patients were treated with either 33M (n=3) or 100M (n=3) CAR T-cell dose levels using a bendamustine lymphodepleting (LD) regimen.<\/p>\n<p>The oral presentation features updated data from six patients with available efficacy data from five patients, with follow-up of more than two years in the longest-treated patient. Key highlights include:<\/p>\n<p>\n        <strong>Efficacy:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>All five patients with available data demonstrated stable to improved expanded disability status scale scores (EDSS) as of last follow-up, with the majority (4\/5) showing sustained clinical benefit through one year.<\/li>\n<li>Four patients with more than one-year of follow-up sustained improvement without further need for chronic immunotherapies. The first patient treated with miv-cel achieved sustained clinical benefit beyond two years.\n<\/li>\n<\/ul>\n<p>\n        <strong>Biological activity: <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Robust CAR T-cell expansion detected in peripheral blood and penetration in cerebrospinal fluid (CSF), with peak levels at approximately day 14.<\/li>\n<li>Complete depletion of CD19-positive peripheral B cells was achieved in all participants, followed by repopulation beginning at month 3, consistent with the emergence of na\u00efve B cells, supporting evidence of immune reset.<\/li>\n<li>Additional biomarker data, including CSF oligoclonal bands and kappa free light chain, continue to support favorable immunological impact at one year.\n<\/li>\n<\/ul>\n<p>\n        <strong>Safety: <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Consistent, well-tolerated safety profile with no high-grade CRS and no reported cases of ICANS or IEC-HS.\n<\/li>\n<\/ul>\n<p>\u201cWe are encouraged by the long-term durability and safety results with miv-cel in progressive multiple sclerosis, which add to the strong body of evidence supporting miv-cel\u2019s transformative potential across neurologic autoimmune diseases,\u201d said Naji Gehchan, Chief Medical and Development Officer of Kyverna Therapeutics. \u201cThe consistent, durable clinical benefit and well-tolerated safety profile observed across our indications are underpinned by miv-cel\u2019s unique construct, specifically developed by Kyverna in autoimmune disease to enable immune reset by deeply and broadly depleting B-cells with a single dose.\u00a0With our RMAT designation, we look forward to working with the FDA on our development plan in progressive multiple sclerosis and providing an update by early 2027.\u201d<\/p>\n<p>\n        <strong>About miv-cel (mivocabtagene autoleucel, KYV-101)<\/strong><br \/>\n        <br \/>Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.<\/p>\n<p>\n        <strong>About Multiple Sclerosis<\/strong><br \/>\n        <br \/>Multiple sclerosis is a chronic autoimmune disease causing neurodegeneration, in which patients can experience a range of symptoms including blurred vision, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, and, in severe cases, the inability to walk or stand, B cells play a significant role in MS by producing autoantibodies that attack the protective sheath around the nerves, activating T cells, and increasing inflammation. Current disease-modifying treatments for MS aim to reduce the frequence of disease relapse and delay a progression of disability, but the disease remains a chronic condition that will progressively worsen for most patients.<\/p>\n<p>\n        <strong>About Kyverna Therapeutics<\/strong><br \/>\n        <br \/>Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases.\u00a0Kyverna\u2019s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).<\/p>\n<p>Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy&#8217;s potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9cRQ2q6mQke001edeA5-KbUoEMlpFpwooli0TzZeLOin8UMNVh0SGsNAGXW0rA-hl0ux3o61o_ojQJb57tSk2HGok1f7CIaeca7hIiB9WSU=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/kyvernatx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements.\u201d The words, without limitation, \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: miv-cel\u2019s potential to meaningfully alter the course of, or offer a novel approach to treating, progressive multiple sclerosis; miv-cel\u2019s transformative potential across neurologic autoimmune diseases; Kyverna\u2019s development plans in progressive multiple sclerosis and expected timing for providing an update on its development strategy for multiple sclerosis; the potential for miv-cel to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose or to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; Kyverna\u2019s pipeline opportunities; and Kyverna\u2019s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the \u201cRisk Factors\u201d section of Kyverna\u2019s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna\u2019s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Investors:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FiYfQDsXmtSn7R4yMMHX2JUAFyHRntyLkmRfyH9Ve5oyUKSjk0gEiFLYhBnKIFp11TJ4vCRN3owawu9NZgz9tHIH3B9j9ZQ8KOWsiEghAtnMkWBtzFqx3qnR2UIcsVCWJqz-w0ar5S9M3VX00IbktA==\" rel=\"nofollow\" target=\"_blank\"><u>InvestorRelations@kyvernatx.com<\/u><\/a><br \/>Media:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v3Asury8VezlxStWdVdwpwT8kLNdfI6ojV2vl3h3MncCJ_CCerOBEYPa2jNikDesM_XC0Qo-PiPenGcbflZyv3h77YwFgwyOAM1v3OLvbu4=\" rel=\"nofollow\" target=\"_blank\"><u>media@kyvernatx.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmViMjBhYTEtMzMwZC00ZmRmLTk0MTYtMzUzMmU3ZWUyOTRmLTEyNzQzMjItMjAyNi0xMC0yMy1lbg==\/tiny\/Kyverna-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies Durable results extending beyond two years in the first patient treated Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027 EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1 investigator-initiated trial (IIT) of miv-cel &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013176","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies Durable results extending beyond two years in the first patient treated Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027 EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1 investigator-initiated trial (IIT) of miv-cel &hellip; Continue reading &quot;Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T14:35:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026\",\"datePublished\":\"2026-10-23T14:35:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/\"},\"wordCount\":1375,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/\",\"name\":\"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=\",\"datePublished\":\"2026-10-23T14:35:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/","og_locale":"en_US","og_type":"article","og_title":"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - Market Newsdesk","og_description":"Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies Durable results extending beyond two years in the first patient treated Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027 EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) &#8212; Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1 investigator-initiated trial (IIT) of miv-cel &hellip; Continue reading \"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-23T14:35:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026","datePublished":"2026-10-23T14:35:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/"},"wordCount":1375,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/","name":"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=","datePublished":"2026-10-23T14:35:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTk2MCM3OTEyMzE4IzIyNjI3NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013176"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013176\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}